Medicine and Dentistry
Radiation Therapy
100%
Non Small Cell Lung Cancer
84%
Stereotactic Body Radiation Therapy
81%
Overall Survival
48%
Lung Cancer
44%
Neoplasm
40%
Surgery
32%
Malignant Neoplasm
22%
Lung
21%
Stereotactic Radiosurgery
20%
Oncology
19%
Brain Metastasis
18%
Ventricular Tachycardia
17%
Magnetic Resonance Imaging
17%
Diseases
17%
Chemoradiotherapy
16%
Adaptive Radiation
14%
Progression Free Survival
14%
Clinical Trial
13%
Non-Small Cell Lung Cancer
13%
Hazard Ratio
12%
Clinical Stage
12%
Breathing
12%
Adaptive Radiotherapy
12%
Intensity Modulated Radiation Therapy
12%
Computer Assisted Tomography
11%
Recurrent Disease
11%
Esophageal Cancer
11%
Meningioma
10%
Radiation Oncology
10%
Immunotherapy
10%
Adverse Event
10%
Metastatic Carcinoma
9%
Treatment Planning
9%
Phase I Trials
9%
Odds Ratio
9%
Adjuvant Chemotherapy
8%
Polyethylene Terephthalate
8%
Cardiac Dysrhythmia
8%
Cancer
7%
Temozolomide
7%
Comorbidity
7%
Cardiotoxicity
7%
Proton Therapy
7%
Chest
7%
Proportional Hazards Model
7%
Radiation Oncologist
7%
Arm
6%
Esophagectomy
6%
Glioblastoma
6%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
63%
Stereotactic Body Radiation Therapy
58%
Radiation Therapy
56%
Overall Survival
45%
NRG Oncology
26%
Confidence Interval
24%
Lung Cancer
23%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
22%
Stereotactic Radiosurgery
21%
Radiotherapy
20%
Brain Metastases
20%
Local Control
20%
Adaptive Radiotherapy
19%
Stereotactic Body Radiotherapy
19%
Ventricular Tachycardia
16%
Tumor
16%
Hazard Ratio
14%
Progression-free Survival
14%
Stage I Lung Cancer
14%
National Cancer Database
14%
At-risk
13%
Cardiac Ablation
13%
Dose Escalation
12%
Stage III Non-small Cell Lung Cancer
12%
Radiation Oncology
12%
Organs at Risk
12%
Magnetic Resonance Imaging
11%
Early-stage Lung Cancer
11%
Internal Target Volume
11%
Chemoradiation
11%
Phase I Trial
11%
Surgical Resection
10%
Chemotherapy
10%
Adjuvant Chemotherapy
10%
Planning Target Volume
10%
Temozolomide
10%
Concurrent Chemotherapy
9%
Dosimetric Predictors
9%
Esophageal Cancer
9%
Adaptive Radiation Therapy
9%
Odds Ratio
9%
Radiation Therapy Oncology Group
8%
Adaptation Planning
8%
Thorax
8%
Phase II Trial
8%
Dosimetric
8%
Positron Emission Tomography
8%
Clinical Experience
7%
Intensity-modulated Radiation Therapy
7%
Hippocampal Avoidance
7%